Overview

SGLT2 Inhibitor for Severe Tricuspid Regurgitation

Status:
Recruiting
Trial end date:
2025-03-03
Target enrollment:
Participant gender:
Summary
The purpose of this study to identify the efficacy of sodium glucose cotransporter 2 inhibitors add-on treatment on right ventricular remodeling and the amount of severe tricuspid regurgitation (TR) in patients with isolated severe TR.
Phase:
N/A
Details
Lead Sponsor:
Samsung Medical Center
Treatments:
Dapagliflozin